New Clinical and Real-World Data Support Use of DARZALEX

Investigational daratumumab quadruple combination regimen shows responses in newly diagnosed, transplant-eligible patients with multiple myeloma in randomised Phase 2 GRIFFIN study1 Real-world...

Related Keywords

United States , American , Edmond Chan Mbch , Jacob Laubach , Imran Khan , American Society Of Clinical Oncology , Janssen Biotech Inc , American Society Of Hematology Annual Meeting , Jerome Lipper Multiple Myeloma Center , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , American Society Of Hematology , Janssen Scientific Affairs , Dana Farber Cancer Institute , American Cancer Society , None Of The Janssen Pharmaceutical Companies , European Commission , Flatiron Health , Exchange Commission , Companies Of Johnson , European Commission Grants Marketing Authorisation , European Medicines Agency , Johnson , American Society , Edmond Chan , Area Lead Haematology , Clinical Director , Medical Affairs , New England Journal , Real World Data , Janssen Biotech , Product Characteristics , Pharmaceutical Companies , Infectious Diseases , Janssen Cilag Limited , Private Securities Litigation Reform Act , Janssen Pharmaceutica , Annual Report , Note Regarding Forward Looking , Quarterly Report , Plus Lenalidomide , Updated Analysis , Oral Presentation To Be Presented , Hematology Annual , First Line Use , Dexamethasone Confers Survival Benefit Compared , Second Line Use , Daratumumab Based Regimens , Transplant Ineligible Patients , Multiple Myeloma , Different Clinical , Real World Patient Characteristics , Dexamethasone As First Line , Newly Diagnosed Multiple Myeloma , Impaired Renal Function , Study Based , Lenalidomide Starting , Comparing Daratumumab , Versus Lenalidomide , Subjects With Newly Diagnosed Multiple Myeloma , Dexamethasone With Lenalidomide , Commission Grants Marketing Authorisation , Subcutaneous Formulation , Dexamethasone Versus Bortezomib , Patients With Previously Treated Multiple Myeloma , Three Year Follow Up , Lymphoma Myeloma , Today Population Factsheets , ,